The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment
- 83 Downloads
The prevalence of nausea/vomiting in patients with advanced cancer has a wide range. Due to a very low level of evidence regarding antiemetic treatment, current guidelines recommend an etiology-based approach. The evidence for this approach is also slim and research is urgently needed.
(Part One) to elucidate the prevalence of nausea and the possible associations with sociodemographic and clinical variables and (Part Two) to investigate possible etiologies of nausea and antiemetic treatments initiated in patients with nausea.
Patients with advanced cancer and no recent antineoplastic treatment were included in a prospective two-part study. In Part One, patients completed an extended version of the EORTC QLQ-C15-PAL. Nauseated patients could then be included in Part Two in which possible etiologies and antiemetic treatment were recorded and a follow-up questionnaire was completed.
Eight hundred twenty-one patients were included and 46% reported any degree of nausea. Younger age and female sex were associated with a higher degree of nausea. Common etiologies included constipation, opioid use, and “other,” and treatments associated with a statistically significant decrease in nausea/vomiting were olanzapine, laxatives, corticosteroids, domperidone, and metoclopramide.
Nausea was a common symptom in this patient population and many different etiologies were suggested. Most patients reported a lower degree of nausea at follow-up. More research in treatment approaches and specific antiemetics is strongly needed.
KeywordsNausea Advanced cancer N/V Etiology Treatment
Funding was obtained from The Danish Cancer Society, the IMK foundation, and the Region of Southern Denmark. The funding sources had no influence on design, conduction, analyses of results, or manuscript writing.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 7.Delgado-Guay MO, Rodriguez-Nunez A, Shin SH, Chisholm G, Williams J, Frisbee-Hume S, Bruera E (2016) Characteristics and outcomes of patients with advanced cancer evaluated by a palliative care team at an emergency center. A retrospective study. Support Care Cancer 24(5):2287–2295CrossRefGoogle Scholar
- 10.Harder SL, Groenvold M, Herrstedt J, Johnsen AT (2019) Nausea in advanced cancer: relationships between intensity, burden, and the need for help. Support Care Cancer 27(1):265–273Google Scholar
- 14.Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB, EORTC Quality of Life Group (2006) The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 42(1):55–64CrossRefGoogle Scholar
- 15.Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Dirven L, Fayers P, Gamper EM, Giesinger JM, Habets EJJ, Hammerlid E, Helbostad J, Hjermstad MJ, Holzner B, Johnson C, Kemmler G, King MT, Kaasa S, Loge JH, Reijneveld JC, Singer S, Taphoorn MJB, Thamsborg LH, Tomaszewski KA, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (2018) The EORTC CAT Core-the computer adaptive version of the EORTC QLQ-C30 questionnaire. Eur J Cancer 100:8–16CrossRefGoogle Scholar
- 16.Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European organisation for research and treatment of cancer, BrusselsGoogle Scholar
- 17.Groenvold M, Petersen MA (2006) Addendum to the EORTC QLQ-C30 scoring manual: scoring of the EORTC QLQ-C15-PAL. European organisation for research and treatment of cancer, BrusselsGoogle Scholar
- 32.Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwöhner K, Schulenberg D, Radbruch L, Working Group on the Core Documentation for Palliative Care Units in Germany (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18(2):100–107CrossRefGoogle Scholar
- 34.Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M (2017) NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Cancer Netw 15(7):883–893CrossRefGoogle Scholar
- 36.Available from: http://pro.medicin.dk/Generelt/Nyheder/222. Accessed Sep 2018